25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

1BT (Enlivex) Stock Analysis
Buy, Hold or Sell?

Let's analyze Enlivex together

I guess you are interested in Enlivex Therapeutics Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – Enlivex’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – Enlivex’s Price Targets

I'm going to help you getting a better view of Enlivex Therapeutics Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Enlivex Therapeutics Ltd

I send you an email if I find something interesting about Enlivex Therapeutics Ltd.

1. Quick Overview

1.1. Quick analysis of Enlivex (30 sec.)










1.2. What can you expect buying and holding a share of Enlivex? (30 sec.)

How much money do you get?

How much money do you get?
€0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
€0.76
Expected worth in 1 year
€0.53
How sure are you?
23.5%

+ What do you gain per year?

Total Gains per Share
€-0.23
Return On Investment
-17.7%

For what price can you sell your share?

Current Price per Share
€1.29
Expected price per share
€1.19 - €1.3
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Enlivex (5 min.)




Live pricePrice per Share (EOD)
€1.29
Intrinsic Value Per Share
€-7.13 - €-8.22
Total Value Per Share
€-6.37 - €-7.46

2.2. Growth of Enlivex (5 min.)




Is Enlivex growing?

Current yearPrevious yearGrowGrow %
How rich?$20.6m$35m-$10.1m-40.9%

How much money is Enlivex making?

Current yearPrevious yearGrowGrow %
Making money-$3.5m-$6.4m$2.9m81.4%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

2.3. Financial Health of Enlivex (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#512 / 868

Most Revenue
#738 / 868

Most Profit
#361 / 868

Most Efficient
#371 / 868
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Enlivex?

Welcome investor! Enlivex's management wants to use your money to grow the business. In return you get a share of Enlivex.

First you should know what it really means to hold a share of Enlivex. And how you can make/lose money.

Speculation

The Price per Share of Enlivex is €1.29. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Enlivex.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Enlivex, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is €0.76. Based on the TTM, the Book Value Change Per Share is €-0.06 per quarter. Based on the YOY, the Book Value Change Per Share is €-0.22 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is €0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Enlivex.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 β‚¬% of Price per Share€% of Price per Share€% of Price per Share€% of Price per Share€% of Price per Share€% of Price per Share
Usd Eps-0.14-11.2%-0.15-11.6%-0.27-21.1%-0.24-18.9%-0.22-16.8%-0.16-12.2%
Usd Book Value Change Per Share-0.12-9.6%-0.07-5.1%-0.25-19.3%-0.20-15.4%-0.02-1.9%0.032.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.12-9.6%-0.07-5.1%-0.25-19.3%-0.20-15.4%-0.02-1.9%0.032.0%
Usd Price Per Share1.06-1.38-2.72-2.83-4.67-5.33-
Price to Earnings Ratio-1.82--2.51--2.86--3.01--6.70--12.99-
Price-to-Total Gains Ratio-8.51--4.15--13.44--11.20--46.08--39.71-
Price to Book Ratio1.22-1.32-2.01-1.70-2.29-7.85-
Price-to-Total Gains Ratio-8.51--4.15--13.44--11.20--46.08--39.71-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.473309
Number of shares678
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.07-0.02
Usd Total Gains Per Share-0.07-0.02
Gains per Quarter (678 shares)-44.23-16.25
Gains per Year (678 shares)-176.94-65.00
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-177-1870-65-75
20-354-3640-130-140
30-531-5410-195-205
40-708-7180-260-270
50-885-8950-325-335
60-1062-10720-390-400
70-1239-12490-455-465
80-1416-14260-520-530
90-1592-16030-585-595
100-1769-17800-650-660

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.034.00.00.0%0.034.00.00.0%
Book Value Change Per Share1.03.00.025.0%1.011.00.08.3%3.017.00.015.0%8.025.01.023.5%8.025.01.023.5%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.034.00.0%0.00.034.00.0%
Total Gains per Share1.03.00.025.0%1.011.00.08.3%3.017.00.015.0%8.025.01.023.5%8.025.01.023.5%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Enlivex Therapeutics Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.109-0.057-47%-0.218+100%-0.174+60%-0.021-81%0.022-588%
Book Value Per Share--0.7570.912-17%1.285-41%1.464-48%1.844-59%1.232-39%
Current Ratio--7.2038.454-15%6.735+7%8.674-17%10.874-34%9.310-23%
Debt To Asset Ratio--0.1420.126+13%0.164-14%0.143-1%0.129+10%0.149-5%
Debt To Equity Ratio--0.1650.144+15%0.197-16%0.168-2%0.149+11%0.181-9%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value--19077145.07525811341.069-26%50798123.800-62%53337422.823-64%91634592.434-79%106777223.496-82%
Eps---0.127-0.131+4%-0.239+88%-0.214+69%-0.190+50%-0.138+9%
Free Cash Flow Per Share---0.171-0.121-29%-0.205+20%-0.212+24%-0.194+13%-0.183+7%
Free Cash Flow To Equity Per Share---0.164-0.065-60%-0.200+22%-0.191+17%-0.030-82%0.012-1492%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%0.941+6%
Intrinsic Value_10Y_max---8.220----------
Intrinsic Value_10Y_min---7.132----------
Intrinsic Value_1Y_max---0.847----------
Intrinsic Value_1Y_min---0.832----------
Intrinsic Value_3Y_max---2.526----------
Intrinsic Value_3Y_min---2.412----------
Intrinsic Value_5Y_max---4.185----------
Intrinsic Value_5Y_min---3.886----------
Market Cap30766371.000+28%22061189.87528888199.469-24%56882011.500-61%59181542.056-63%97614064.834-77%111224009.602-80%
Net Profit Margin----0%-0%-0%-0%-0%
Operating Margin----0%-0%-0%-0%-0%
Operating Ratio----0%-0%-0%-0%-0%
Pb Ratio1.703+28%1.2211.322-8%2.013-39%1.695-28%2.293-47%7.851-84%
Pe Ratio-2.545-39%-1.825-2.513+38%-2.856+57%-3.007+65%-6.702+267%-12.995+612%
Price Per Share1.290+28%0.9251.211-24%2.385-61%2.481-63%4.093-77%4.664-80%
Price To Free Cash Flow Ratio-1.887-39%-1.353-3.015+123%-3.050+125%-3.105+130%-6.342+369%-2.578+91%
Price To Total Gains Ratio-11.863-39%-8.506-4.149-51%-13.443+58%-11.203+32%-46.084+442%-39.711+367%
Quick Ratio--5.8846.700-12%5.674+4%5.374+9%7.358-20%4.698+25%
Return On Assets---0.144-0.129-10%-0.159+11%-0.132-8%-0.106-26%-0.144+0%
Return On Equity---0.167-0.148-11%-0.191+14%-0.155-7%-0.124-26%-0.156-7%
Total Gains Per Share---0.109-0.057-47%-0.218+100%-0.174+60%-0.021-81%0.022-588%
Usd Book Value--20627469.47124841815.387-17%35013046.879-41%39883324.390-48%50218742.953-59%33561675.611-39%
Usd Book Value Change Per Share---0.124-0.065-47%-0.249+100%-0.199+60%-0.024-81%0.025-588%
Usd Book Value Per Share--0.8651.042-17%1.468-41%1.672-48%2.106-59%1.407-39%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value--21788007.39029479132.635-26%58016537.192-62%60916670.606-64%104655868.019-79%121950266.955-82%
Usd Eps---0.145-0.150+4%-0.272+88%-0.244+69%-0.217+50%-0.158+9%
Usd Free Cash Flow---4656105.971-3303575.188-29%-5591627.263+20%-5781798.257+24%-5276820.098+13%-3082246.621-34%
Usd Free Cash Flow Per Share---0.195-0.139-29%-0.234+20%-0.242+24%-0.221+13%-0.209+7%
Usd Free Cash Flow To Equity Per Share---0.187-0.074-60%-0.229+22%-0.218+17%-0.035-82%0.013-1492%
Usd Market Cap35138272.319+28%25196084.95632993212.613-24%64964945.334-61%67591239.182-63%111485023.447-77%127028941.367-80%
Usd Price Per Share1.473+28%1.0561.383-24%2.724-61%2.834-63%4.674-77%5.326-80%
Usd Profit---3452078.568-3581581.515+4%-6497647.883+88%-5864216.800+70%-5204718.457+51%-3712055.073+8%
Usd Revenue----0%-0%-0%-0%-0%
Usd Total Gains Per Share---0.124-0.065-47%-0.249+100%-0.199+60%-0.024-81%0.025-588%
 EOD+5 -3MRQTTM+5 -26YOY+21 -103Y+18 -135Y+9 -2210Y+13 -19

3.3 Fundamental Score

Let's check the fundamental score of Enlivex Therapeutics Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-2.545
Price to Book Ratio (EOD)Between0-11.703
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than15.884
Current Ratio (MRQ)Greater than17.203
Debt to Asset Ratio (MRQ)Less than10.142
Debt to Equity Ratio (MRQ)Less than10.165
Return on Equity (MRQ)Greater than0.15-0.167
Return on Assets (MRQ)Greater than0.05-0.144
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Enlivex Therapeutics Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose1.290
Total0/1 (0.0%)

4. In-depth Analysis

4.1 About Enlivex Therapeutics Ltd

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra (ENX-CL-02-002), which is in phase II clinical trial for the treatment of organ dysfunction and failure caused by sepsis; and Allocetra (ENX-CL-05-001), which is in phase I/II clinical trial to treat moderate knee osteoarthritis. The company also develops 0189-22-KMC, which is in phase I/II clinical trial to treat end-stage knee osteoarthritis; 0006-24-KMC, which is in phase I/II clinical trial for the treatment of Basal thumb osteoarthritis; and ENX-CL-06-001 to treat Psoriatic arthritis and is in phase I/II clinical trial. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Ness Ziona, Israel.

Fundamental data was last updated by Penke on 2025-07-27 02:56:04.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ Enlivex earns for each €1 of revenue.

  • Above 10% is considered healthy but always compareΒ Enlivex to theΒ Biotechnology industry mean.
  • A Net Profit Margin of 0.0%Β means thatΒ €0.00 for each €1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Enlivex Therapeutics Ltd:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--88.2%+88.2%
TTM--129.4%+129.4%
YOY--187.4%+187.4%
3Y--247.8%+247.8%
5Y--337.6%+337.6%
10Y--472.4%+472.4%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ Enlivex is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ Enlivex to theΒ Biotechnology industry mean.
  • -14.4% Return on Assets means thatΒ Enlivex generatedΒ €-0.14 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Enlivex Therapeutics Ltd:

  • The MRQ is -14.4%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -12.9%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-14.4%TTM-12.9%-1.5%
TTM-12.9%YOY-15.9%+3.0%
TTM-12.9%5Y-10.6%-2.3%
5Y-10.6%10Y-14.4%+3.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-14.4%-11.3%-3.1%
TTM-12.9%-11.2%-1.7%
YOY-15.9%-11.3%-4.6%
3Y-13.2%-11.6%-1.6%
5Y-10.6%-11.9%+1.3%
10Y-14.4%-13.6%-0.8%
4.3.1.3. Return on Equity

Shows how efficient Enlivex is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ Enlivex to theΒ Biotechnology industry mean.
  • -16.7% Return on Equity means Enlivex generated €-0.17Β for eachΒ €1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Enlivex Therapeutics Ltd:

  • The MRQ is -16.7%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -14.8%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-16.7%TTM-14.8%-1.9%
TTM-14.8%YOY-19.1%+4.3%
TTM-14.8%5Y-12.4%-2.5%
5Y-12.4%10Y-15.6%+3.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-16.7%-13.2%-3.5%
TTM-14.8%-14.2%-0.6%
YOY-19.1%-14.3%-4.8%
3Y-15.5%-16.5%+1.0%
5Y-12.4%-17.4%+5.0%
10Y-15.6%-19.5%+3.9%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Enlivex Therapeutics Ltd.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient Enlivex is operatingΒ .

  • Measures how much profit Enlivex makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ Enlivex to theΒ Biotechnology industry mean.
  • An Operating Margin of 0.0%Β means the company generated €0.00 Β for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Enlivex Therapeutics Ltd:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--207.3%+207.3%
TTM--250.3%+250.3%
YOY--204.2%+204.2%
3Y--214.9%+214.9%
5Y--328.2%+328.2%
10Y--441.4%+441.4%
4.3.2.2. Operating Ratio

Measures how efficient Enlivex is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are €0.00 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of Enlivex Therapeutics Ltd:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.055-2.055
TTM-2.647-2.647
YOY-3.043-3.043
3Y-3.500-3.500
5Y-4.641-4.641
10Y-6.340-6.340
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Enlivex Therapeutics Ltd.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Enlivex is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Biotechnology industry mean).
  • A Current Ratio of 7.20Β means the company has €7.20 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of Enlivex Therapeutics Ltd:

  • The MRQ is 7.203. The company is very able to pay all its short-term debts. +2
  • The TTM is 8.454. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ7.203TTM8.454-1.251
TTM8.454YOY6.735+1.719
TTM8.4545Y10.874-2.420
5Y10.87410Y9.310+1.564
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ7.2033.612+3.591
TTM8.4543.830+4.624
YOY6.7354.090+2.645
3Y8.6744.639+4.035
5Y10.8745.692+5.182
10Y9.3106.086+3.224
4.4.3.2. Quick Ratio

Measures if Enlivex is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ Enlivex to theΒ Biotechnology industry mean.
  • A Quick Ratio of 5.88Β means the company can pay off €5.88 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Enlivex Therapeutics Ltd:

  • The MRQ is 5.884. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 6.700. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ5.884TTM6.700-0.816
TTM6.700YOY5.674+1.026
TTM6.7005Y7.358-0.658
5Y7.35810Y4.698+2.660
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.8842.960+2.924
TTM6.7003.185+3.515
YOY5.6743.776+1.898
3Y5.3744.368+1.006
5Y7.3585.710+1.648
10Y4.6986.289-1.591
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Enlivex Therapeutics Ltd.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of EnlivexΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ Enlivex to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.14Β means that Enlivex assets areΒ financed with 14.2% credit (debt) and the remaining percentage (100% - 14.2%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of Enlivex Therapeutics Ltd:

  • The MRQ is 0.142. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.126. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.142TTM0.126+0.016
TTM0.126YOY0.164-0.038
TTM0.1265Y0.129-0.003
5Y0.12910Y0.149-0.020
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1420.339-0.197
TTM0.1260.356-0.230
YOY0.1640.335-0.171
3Y0.1430.343-0.200
5Y0.1290.347-0.218
10Y0.1490.382-0.233
4.5.4.2. Debt to Equity Ratio

Measures ifΒ Enlivex is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ Enlivex to theΒ Biotechnology industry mean.
  • A Debt to Equity ratio of 16.5% means that company has €0.17 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Enlivex Therapeutics Ltd:

  • The MRQ is 0.165. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.144. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.165TTM0.144+0.021
TTM0.144YOY0.197-0.053
TTM0.1445Y0.149-0.005
5Y0.14910Y0.181-0.031
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1650.383-0.218
TTM0.1440.438-0.294
YOY0.1970.416-0.219
3Y0.1680.452-0.284
5Y0.1490.466-0.317
10Y0.1810.523-0.342
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every €1 in earnings Enlivex generates.

  • Above 15 is considered overpriced butΒ always compareΒ Enlivex to theΒ Biotechnology industry mean.
  • A PE ratio of -1.82 means the investor is paying €-1.82Β for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Enlivex Therapeutics Ltd:

  • The EOD is -2.545. Based on the earnings, the company is expensive. -2
  • The MRQ is -1.825. Based on the earnings, the company is expensive. -2
  • The TTM is -2.513. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.545MRQ-1.825-0.720
MRQ-1.825TTM-2.513+0.689
TTM-2.513YOY-2.856+0.342
TTM-2.5135Y-6.702+4.189
5Y-6.70210Y-12.995+6.293
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.545-2.481-0.064
MRQ-1.825-2.070+0.245
TTM-2.513-2.657+0.144
YOY-2.856-3.743+0.887
3Y-3.007-3.711+0.704
5Y-6.702-6.177-0.525
10Y-12.995-6.833-6.162
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Enlivex Therapeutics Ltd:

  • The EOD is -1.887. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -1.353. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -3.015. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.887MRQ-1.353-0.534
MRQ-1.353TTM-3.015+1.662
TTM-3.015YOY-3.050+0.035
TTM-3.0155Y-6.342+3.328
5Y-6.34210Y-2.578-3.764
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.887-3.900+2.013
MRQ-1.353-2.798+1.445
TTM-3.015-3.829+0.814
YOY-3.050-4.298+1.248
3Y-3.105-5.070+1.965
5Y-6.342-8.476+2.134
10Y-2.578-9.070+6.492
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ Enlivex is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Biotechnology industry mean).
  • A PB ratio of 1.22 means the investor is paying €1.22Β for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of Enlivex Therapeutics Ltd:

  • The EOD is 1.703. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.221. Based on the equity, the company is underpriced. +1
  • The TTM is 1.322. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.703MRQ1.221+0.482
MRQ1.221TTM1.322-0.100
TTM1.322YOY2.013-0.692
TTM1.3225Y2.293-0.971
5Y2.29310Y7.851-5.558
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.7032.247-0.544
MRQ1.2211.857-0.636
TTM1.3222.125-0.803
YOY2.0132.502-0.489
3Y1.6952.485-0.790
5Y2.2933.666-1.373
10Y7.8514.337+3.514
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2025-03-31. Currency in USD. All numbers in thousands.

Summary
Total Assets24,035
Total Liabilities3,408
Total Stockholder Equity20,627
 As reported
Total Liabilities 3,408
Total Stockholder Equity+ 20,627
Total Assets = 24,035

Assets

Total Assets24,035
Total Current Assets22,647
Long-term Assets1,388
Total Current Assets
Cash And Cash Equivalents 2,053
Short-term Investments 18,498
Total Current Assets  (as reported)22,647
Total Current Assets  (calculated)20,551
+/- 2,096
Long-term Assets
Property Plant Equipment 1,069
Long-term Assets Other 311
Long-term Assets  (as reported)1,388
Long-term Assets  (calculated)1,380
+/- 8

Liabilities & Shareholders' Equity

Total Current Liabilities3,144
Long-term Liabilities264
Total Stockholder Equity20,627
Total Current Liabilities
Accounts payable 533
Total Current Liabilities  (as reported)3,144
Total Current Liabilities  (calculated)533
+/- 2,611
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt503
Long-term Liabilities  (as reported)264
Long-term Liabilities  (calculated)503
+/- 239
Total Stockholder Equity
Total Stockholder Equity (as reported)20,627
Total Stockholder Equity (calculated)0
+/- 20,627
Other
Capital Stock2,707
Common Stock Shares Outstanding 23,850
Net Invested Capital 20,627
Net Working Capital 19,503
Property Plant and Equipment Gross 4,858



6.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-31
> Total Assets 
10,630
7,886
5,514
4,283
3,622
1,704
1,704
12,130
11,034
19,046
20,829
19,217
17,560
37,651
35,437
33,372
40,358
95,962
95,187
98,167
95,146
88,621
77,341
72,414
67,642
60,022
53,028
46,936
36,831
31,047
31,902
29,797
27,687
24,035
24,03527,68729,79731,90231,04736,83146,93653,02860,02267,64272,41477,34188,62195,14698,16795,18795,96240,35833,37235,43737,65117,56019,21720,82919,04611,03412,1301,7041,7043,6224,2835,5147,88610,630
   > Total Current Assets 
10,541
7,799
5,514
4,283
3,622
1,704
1,704
11,590
10,277
17,778
19,578
18,068
16,421
36,604
34,334
31,606
38,121
93,776
92,828
90,281
86,442
79,299
65,051
59,231
52,330
37,581
30,785
31,841
33,764
28,376
28,570
27,111
25,993
22,647
22,64725,99327,11128,57028,37633,76431,84130,78537,58152,33059,23165,05179,29986,44290,28192,82893,77638,12131,60634,33436,60416,42118,06819,57817,77810,27711,5901,7041,7043,6224,2835,5147,79910,541
       Cash And Cash Equivalents 
6,871
4,100
5,163
4,105
3,526
1,674
1,674
11,351
9,736
13,642
14,548
5,448
3,948
22,666
10,163
4,148
5,673
4,089
12,612
22,146
11,202
67,666
20,151
57,655
47,822
13,138
3,458
1,971
813
1,913
3,747
2,772
3,301
2,053
2,0533,3012,7723,7471,9138131,9713,45813,13847,82257,65520,15167,66611,20222,14612,6124,0895,6734,14810,16322,6663,9485,44814,54813,6429,73611,3511,6741,6743,5264,1055,1634,1006,871
       Short-term Investments 
3,007
3,017
0
0
0
0
0
40
40
40
41
8,017
8,060
10,008
20,043
24,028
30,034
87,577
77,988
65,484
72,928
10,336
42,334
0
299
22,839
25,443
28,527
26,507
21,523
22,195
21,733
20,195
18,498
18,49820,19521,73322,19521,52326,50728,52725,44322,839299042,33410,33672,92865,48477,98887,57730,03424,02820,04310,0088,0608,01741404040000003,0173,007
       Net Receivables 
52
682
342
178
28
30
30
161
213
2,092
2,751
2,445
2,403
571
751
717
0
0
0
0
0
0
0
1,463
647
1,604
1,884
1,343
0
0
0
0
0
0
0000001,3431,8841,6046471,46300000007177515712,4032,4452,7512,09221316130302817834268252
       Other Current Assets 
0
0
9
0
0
0
0
0
0
1,500
1,500
1,500
1,500
2,937
2,669
2,144
1,250
1,225
883
874
113
113
113
113
0
0
113
0
0
0
0
0
0
0
0000000113001131131131138748831,2251,2502,1442,6692,9371,5001,5001,5001,500000000900
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
1,268
1,251
1,149
1,139
1,047
1,103
1,766
2,237
2,186
2,359
7,886
8,704
9,322
12,290
13,183
15,312
22,441
22,243
15,095
3,067
2,671
3,332
2,686
1,694
1,388
1,3881,6942,6863,3322,6713,06715,09522,24322,44115,31213,18312,2909,3228,7047,8862,3592,1862,2371,7661,1031,0471,1391,1491,2511,268000000000
       Property Plant Equipment 
71
68
0
0
0
0
0
469
685
1,205
1,186
1,083
1,058
978
1,038
1,656
2,140
2,095
2,265
7,573
2,530
8,874
11,886
12,761
14,900
14,791
14,308
14,299
2,580
2,242
2,028
1,771
1,153
1,069
1,0691,1531,7712,0282,2422,58014,29914,30814,79114,90012,76111,8868,8742,5307,5732,2652,0952,1401,6561,0389781,0581,0831,1861,205685469000006871
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000300000000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
410
365
342
646
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000646342365410000000000000
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
521
488
469
76
64
60
105
89
86
88
307
321
312
286
283
299
294
291
284
300
312
306
311
317
311
311317311306312300284291294299283286312321307888689105606476469488521000000000
> Total Liabilities 
1,931
1,618
792
537
460
144
144
967
1,136
5,590
5,468
5,434
6,278
5,592
5,245
4,873
4,871
5,357
4,981
10,084
10,107
10,969
8,855
9,140
10,801
9,448
8,693
8,157
6,747
4,196
3,340
3,210
4,098
3,408
3,4084,0983,2103,3404,1966,7478,1578,6939,44810,8019,1408,85510,96910,10710,0844,9815,3574,8714,8735,2455,5926,2785,4345,4685,5901,1369671441444605377921,6181,931
   > Total Current Liabilities 
1,931
1,618
792
537
460
144
144
960
1,130
4,692
5,199
4,550
5,980
5,336
5,009
4,374
4,372
4,908
4,576
4,732
4,718
5,743
4,213
4,529
6,607
5,453
4,991
4,339
6,061
3,609
2,841
2,791
3,799
3,144
3,1443,7992,7912,8413,6096,0614,3394,9915,4536,6074,5294,2135,7434,7184,7324,5764,9084,3724,3745,0095,3365,9804,5505,1994,6921,1309601441444605377921,6181,931
       Short-term Debt 
0
0
0
0
0
0
0
0
0
159
148
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000148159000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
159
148
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000148159000000000
       Accounts payable 
700
543
89
72
19
13
13
128
173
279
321
137
316
209
524
334
288
347
558
1,062
878
1,358
667
1,056
1,948
1,483
1,554
794
827
643
303
92
811
533
533811923036438277941,5541,4831,9481,0566671,3588781,0625583472883345242093161373212791731281313197289543700
       Other Current Liabilities 
0
0
0
0
0
0
0
229
222
3,500
3,500
3,514
3,400
3,044
2,524
1,999
1,171
1,146
793
792
113
113
113
113
0
0
0
0
1,233
0
0
0
142
0
01420001,23300001131131131137927931,1461,1711,9992,5243,0443,4003,5143,5003,5002222290000000
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
898
269
884
298
256
236
499
499
449
405
5,352
5,389
5,226
4,642
4,611
4,194
3,995
3,702
3,818
686
587
499
419
299
264
2642994194995876863,8183,7023,9954,1944,6114,6425,2265,3895,352405449499499236256298884269898000000000
       Other Liabilities 
0
0
0
0
0
0
0
7
6
611
7
637
0
256
0
0
499
449
405
5,352
5,389
5,226
4,642
4,611
0
0
0
0
0
0
0
0
0
0
00000000004,6114,6425,2265,3895,3524054494990025606377611670000000
> Total Stockholder Equity
8,699
6,268
4,722
3,746
3,162
8,028
1,560
10,637
9,182
13,456
15,361
13,783
11,282
32,059
30,192
28,499
35,487
90,605
90,206
88,083
85,039
77,652
68,486
63,274
56,841
50,574
44,335
38,779
30,084
26,851
28,562
26,587
23,589
20,627
20,62723,58926,58728,56226,85130,08438,77944,33550,57456,84163,27468,48677,65285,03988,08390,20690,60535,48728,49930,19232,05911,28213,78315,36113,4569,18210,6371,5608,0283,1623,7464,7226,2688,699
   Common Stock
45
45
46
46
45
46
46
204
396
1,099
1,126
1,151
1,151
1,509
1,513
1,513
1,646
2,104
2,104
2,107
2,107
2,112
2,113
2,116
2,117
0
2,136
0
0
0
0
0
0
0
00000002,13602,1172,1162,1132,1122,1072,1072,1042,1041,6461,5131,5131,5091,1511,1511,1261,09939620446464546464545
   Retained Earnings Total Equity0000000000000000000000000000000000
   Accumulated Other Comprehensive Income 0000000000000000000000000000000000
   Capital Surplus 0000000000000000000000000000000000
   Treasury Stock0000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
-1,916
-2,251
-1,951
-1,717
-1,367
-1,300
-2,316
-1,428
-1,201
977
-1,811
244
1,101
1,101
1,101
1,101
1,101
1,101
0
1,101
0
0
0
0
0
0
0
00000001,10101,1011,1011,1011,1011,1011,101244-1,811977-1,201-1,428-2,316-1,300-1,367-1,717-1,951-2,251-1,9160000000



6.3. Balance Sheets

Currency in USD. All numbers in thousands.




6.4. Cash Flows

Currency in USD. All numbers in thousands.




6.5. Income Statements

Currency in USD. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue0
Cost of Revenue--
Gross Profit-0
 
Operating Income (+$)
Gross Profit-
Operating Expense-14,931
Operating Income-14,931-14,931
 
Operating Expense (+$)
Research Development10,623
Selling General Administrative4,808
Selling And Marketing Expenses-
Operating Expense14,93115,431
 
Net Interest Income (+$)
Interest Income1,069
Interest Expense--
Other Finance Cost-13
Net Interest Income1,056
 
Pretax Income (+$)
Operating Income-14,931
Net Interest Income1,056
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-15,014-13,792
EBIT - interestExpense = 0
-15,014
-15,014
Interest Expense-
Earnings Before Interest and Taxes (EBIT)--15,014
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax-15,014
Tax Provision--
Net Income From Continuing Ops-15,014-15,014
Net Income-15,014
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net-1,139-1,056
 

Technical Analysis of Enlivex
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Enlivex. The general trend of Enlivex is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Enlivex's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Enlivex Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Enlivex Therapeutics Ltd.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 1.28 < 1.28 < 1.3.

The bearish price targets are: 1.26 > 1.19 > 1.19.

Know someone who trades $1BT? Share this with them.πŸ‘‡

Enlivex Therapeutics Ltd Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Enlivex Therapeutics Ltd. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Enlivex Therapeutics Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Enlivex Therapeutics Ltd.

Enlivex Therapeutics Ltd Daily Moving Average Convergence/Divergence (MACD) ChartEnlivex Therapeutics Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Enlivex Therapeutics Ltd. The current adx is .

Enlivex Therapeutics Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Enlivex Therapeutics Ltd.

Enlivex Therapeutics Ltd Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Enlivex Therapeutics Ltd.

Enlivex Therapeutics Ltd Daily Relative Strength Index (RSI) ChartEnlivex Therapeutics Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Enlivex Therapeutics Ltd.

Enlivex Therapeutics Ltd Daily Stochastic Oscillator ChartEnlivex Therapeutics Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Enlivex Therapeutics Ltd.

Enlivex Therapeutics Ltd Daily Commodity Channel Index (CCI) ChartEnlivex Therapeutics Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Enlivex Therapeutics Ltd.

Enlivex Therapeutics Ltd Daily Chande Momentum Oscillator (CMO) ChartEnlivex Therapeutics Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Enlivex Therapeutics Ltd.

Enlivex Therapeutics Ltd Daily Williams %R ChartEnlivex Therapeutics Ltd Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of Enlivex Therapeutics Ltd.

Enlivex Therapeutics Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Enlivex Therapeutics Ltd.

Enlivex Therapeutics Ltd Daily Average True Range (ATR) ChartEnlivex Therapeutics Ltd Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Enlivex Therapeutics Ltd.

Enlivex Therapeutics Ltd Daily On-Balance Volume (OBV) ChartEnlivex Therapeutics Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Enlivex Therapeutics Ltd.

Enlivex Therapeutics Ltd Daily Money Flow Index (MFI) ChartEnlivex Therapeutics Ltd Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Enlivex Therapeutics Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-03-14 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-17 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-18 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-20 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-21 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-03-24 00:00:00SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-25 00:00:00CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-03-26 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-27 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-04-01 00:00:00BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-02 00:00:00MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-04-03 00:00:00MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-04-04 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-04-07 00:00:00BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-08 00:00:00RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-04-09 00:00:00WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-14 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-23 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-24 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-04-25 00:00:00CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-29 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-07 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-08 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-05-14 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-15 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-19 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-05-21 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-05-23 00:00:00CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-05-26 00:00:00MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-05-30 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-06-05 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-09 00:00:00SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-10 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-06-11 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-12 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-06-13 00:00:00SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-06-17 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-19 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-06-23 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-24 00:00:00ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-25 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-26 00:00:00ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-27 00:00:00RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-07-01 00:00:00ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-07-03 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-04 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-08 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-09 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-10 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-11 00:00:00BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-14 00:00:00RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-07-17 00:00:00SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-07-18 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-07-21 00:00:00CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-07-23 00:00:00WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-07-24 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-07-25 00:00:00MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-07-29 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-07-31 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).

6.3. Candlestick Patterns

Enlivex Therapeutics Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Enlivex Therapeutics Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose1.290
Total0/1 (0.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Enlivex with someone you think should read this too:
  • Are you bullish or bearish on Enlivex? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Enlivex? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Enlivex Therapeutics Ltd

I send you an email if I find something interesting about Enlivex Therapeutics Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about Enlivex Therapeutics Ltd.

Receive notifications about Enlivex Therapeutics Ltd in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.